Guidance for Industry on New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products; Availability, 875-876 [E9-31307]
Download as PDF
Federal Register / Vol. 75, No. 3 / Wednesday, January 6, 2010 / Notices
Expenses Section of the Program
Eligibility Guidelines.
Any payment permitted under this
authority must not violate section 301 of
the National Organ Transplant Act of
1984, which makes it ‘‘unlawful for any
person to knowingly acquire, receive, or
otherwise transfer any human organ for
valuable consideration for use in human
transplantation if the transfer affects
interstate commerce.’’ 42 U.S.C. 274e(a).
Certain expenses are excluded from the
scope of valuable consideration,
including ‘‘expenses of travel, housing,
and lost wages incurred by the donor of
a human organ in connection with the
donation of the organ.’’ 42 U.S.C.
274e(c)(2). As the Secretary considers
rulemaking, she will consider this
criminal prohibition in evaluating
which expenses are appropriate for
reimbursement under this Program.
HRSA is seeking public comment as
to whether the Secretary should initiate
rulemaking to allow reimbursement
under this Program for specific
incidental nonmedical expenses and
concerning which incidental
nonmedical expenses should be
included in such rulemaking.
Dated: December 29, 2009.
Mary K. Wakefield,
Administrator.
[FR Doc. E9–31312 Filed 1–5–10; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–D–0525]
Guidance for Industry on New Contrast
Imaging Indication Considerations for
Devices and Approved Drug and
Biological Products; Availability
AGENCY:
Food and Drug Administration,
HHS.
jlentini on DSKJ8SOYB1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘New Contrast Imaging
Indication Considerations for Devices
and Approved Drug and Biological
Products,’’ dated December 2009. As
part of the Medical Device User Fee
Amendments of 2007 (MDUFA)
Commitment for the Performance Goals
and Procedures commitment letter, FDA
agreed to publish guidance for medical
imaging devices for use with imaging
contrast agents or radiopharmaceuticals.
FDA intends this guidance to assist
developers of medical imaging devices
VerDate Nov<24>2008
16:28 Jan 05, 2010
Jkt 220001
and imaging drug/biological products
that provide image contrast
enhancement. The final guidance
announced in this document fulfills
FDA’s commitment to issue guidance
called for by the commitment letter. The
guidance supercedes the draft guidance
of the same title dated September 30,
2008.
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. Submit written comments on
the guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Patricia Y. Love, Office of Combination
Products (HFG–3), Office of the
Commissioner, Food and Drug
Administration, 15800 Crabbs Branch
Way, Rockville, MD 20855, 301–427–
1934.
SUPPLEMENTARY INFORMATION:
I. Background
As part of the Medical Device User
Fee Amendments of 2007 (MDUFA)
Commitment for the Performance Goals
and Procedures, Item I.N of the
September 27, 2007, commitment letter,
FDA agreed to publish draft guidance by
September 30, 2008, for medical
imaging devices for use with imaging
contrast agents or radiopharmaceuticals.
Further, the agreement stated that the
‘‘draft guidance will be published by the
end of FY 2008, and will be subject to
a 90-day comment period. FDA will
issue a final guidance within one year
of the close of the public comment
period.’’ The draft guidance was dated
September 30, 2008 (73 FR 58604,
October 7, 2008); the comment period
closed on January 5, 2009. FDA held
meetings with imaging industry
stakeholders in July 2008 and August
2009. The final guidance announced in
this document fulfills FDA’s
commitment to issue final guidance
called for by the commitment letter. The
guidance supercedes the draft guidance
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
875
of the same title dated September 30,
2008.
FDA is announcing the availability of
guidance for industry entitled ‘‘New
Contrast Imaging Indication
Considerations for Devices and
Approved Drug and Biological
Products.’’ FDA intends this guidance to
assist developers of medical imaging
devices and imaging drug/biological
products that provide image contrast
enhancement. Particularly, this
guidance focuses on the following
topics: (1) When the imaging device
developers may add certain new
imaging contrast indications to their
device for use with already approved
imaging drugs without a need for a
modification of the drug labeling, (2)
when the imaging drug developers may
add certain new imaging contrast
indications to their drug for use with
already approved imaging devices
without a need for a modification of the
device labeling, and (3) what type of
marketing submission(s) imaging drug
or imaging device developers should
submit to FDA to request approval/
clearance to add a new imaging contrast
indication. FDA intends for the
recommendations in this guidance to
promote timely and effective review of,
and consistent and appropriate
regulation and labeling for imaging
drugs and devices.
FDA notes that during the comment
period, certain topics identified in the
docket were beyond the scope of the
guidance document. These comments
included requests for guidance on
developing specific medical imaging
indications (e.g., myocardial perfusion
or breast cancer imaging) and offered
suggestions for the type of acceptable
data. FDA will consider whether
separate guidance would be appropriate.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on ‘‘New Contrast
Imaging Indication Considerations for
Devices and Approved Drug and
Biological Products’’. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR 807 have been approved under
E:\FR\FM\06JAN1.SGM
06JAN1
876
Federal Register / Vol. 75, No. 3 / Wednesday, January 6, 2010 / Notices
OMB control number 0910–0120. The
collections of information in 21 CFR 814
have been approved under OMB control
number 0910–0231. The collections of
information in 21 CFR 314 have been
approved under OMB control number
0910–0001.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Regulatory
Information/Guidances/ucm122047.htm
or https://www.regulations.gov.
Dated: December 30, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–31307 Filed 1–5–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Notice of Meeting; National
Commission on Children and Disasters
AGENCY: Administration for Children
and Families, Department of Health and
Human Services.
ACTION: Notice of meeting.
The meeting will be held on
Tuesday, February 2, 2010, from 9:30
a.m. to 3:30 p.m.
ADDRESSES: The meeting will be held at
the Administration for Children and
Families, 901 D Street, SW.,
Washington, DC 20024. To attend either
in person or via teleconference, please
register by 5 p.m. Eastern Time, January
28, 2010. To register, please e-mail
jacqueline.haye@acf.hhs.gov with
‘‘Meeting Registration’’ in the subject
line, or call (202) 205—9560.
Registration must include your name,
affiliation, and phone number. If you
require a sign language interpreter or
other special assistance, please call
Jacqueline Haye at (202) 205—9560 or e-
jlentini on DSKJ8SOYB1PROD with NOTICES
DATES:
VerDate Nov<24>2008
17:29 Jan 05, 2010
Jkt 220001
mail jacqueline.haye@acf.hhs.gov as
soon as possible and no later than 5
p.m. Eastern Time, January 19, 2010.
Agenda: The Commission will
discuss: (1) Outcomes from the
Commission’s Long-Term Disaster
Recovery Workshop on February 1,
2010; (2) A National resource center on
children and disasters; and (3) Plans for
future work of the Commission.
Written comments may be submitted
electronically to
roberta.lavin@acf.hhs.gov with ‘‘Public
Comment’’ in the subject line. The
Commission recommends that you
include your name, mailing address and
an e-mail address or other contact
information in the body of your
comment. This ensures that you can be
identified as the submitter of the
comment, and it allows the Commission
to contact you if further information on
the substance of the comment is needed
or if your comment cannot be read due
to technical difficulties. The
Commission’s policy is that the
Commission will not edit your
comment, and any identifying or contact
information provided in the body of a
comment will be included as part of the
comment placed in the official record.
The Commission will provide an
opportunity for public comments during
the public meeting on February 2, 2010.
Those wishing to speak will be limited
to three minutes each; speakers are
encouraged to submit their remarks in
writing in advance to ensure their
comment is received in case there is
inadequate time for all comments to be
heard on February 2, 2010.
Additional Information: Contact
Roberta Lavin, Office of Human Services
Emergency Preparedness and Response,
e-mail roberta.lavin@acf.hhs.gov or
(202) 401—9306.
The
National Commission on Children and
Disasters is an independent Commission
that shall conduct a comprehensive
study to examine and assess the needs
of children as they relate to preparation
for, response to, and recovery from all
hazards, building upon the evaluations
of other entities and avoiding
unnecessary duplication by reviewing
the findings, conclusions, and
recommendations of these entities. The
Commission shall then submit a report
to the President and the Congress on the
Commission’s independent and specific
findings, conclusions, and
recommendations to address the needs
of children as they relate to preparation
for, response to, and recovery from all
hazards, including major disasters and
emergencies.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Dated: December 28, 2009.
David A. Hansell,
Principal Deputy Assistant Secretary for
Children and Families.
[FR Doc. E9–31393 Filed 1–5–10; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Anesthetic and Life Support Drugs
Advisory Committee; Cancellation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The meeting of the Anesthetic
and Life Support Drugs Advisory
Committee scheduled for January 28,
2010, is cancelled. This meeting was
announced in the Federal Register of
December 8, 2009 (74 FR 64702). This
meeting has been cancelled to allow
time for the FDA to review new
information that is relevant to the
benefit risk balance for the proposed
new indication. The agency intends to
continue evaluating the application and,
as needed, will announce future
meeting dates in the Federal Register.
FOR FURTHER INFORMATION CONTACT:
Kalyani Bhatt, Center for Drug
Evaluation and Research (HFD–21),
Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630
Fishers Lane, rm. 1093), Rockville, MD
20857, 301–827–7001, FAX: 301–827–
6776, email: Kalyani.Bhatt@fda.hhs.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512529. Please call the
Information Line for up-to-date
information on this meeting.
Dated: December 30, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–31306 Filed 1–5–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
Agency Information Collection
Activities: E-Verify Data Collection
Survey, New Information Collection;
Comment Request
ACTION: 60-Day Notice of Information
Collection Under Review: E-Verify Data
E:\FR\FM\06JAN1.SGM
06JAN1
Agencies
[Federal Register Volume 75, Number 3 (Wednesday, January 6, 2010)]
[Notices]
[Pages 875-876]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-31307]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-D-0525]
Guidance for Industry on New Contrast Imaging Indication
Considerations for Devices and Approved Drug and Biological Products;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry entitled ``New Contrast Imaging
Indication Considerations for Devices and Approved Drug and Biological
Products,'' dated December 2009. As part of the Medical Device User Fee
Amendments of 2007 (MDUFA) Commitment for the Performance Goals and
Procedures commitment letter, FDA agreed to publish guidance for
medical imaging devices for use with imaging contrast agents or
radiopharmaceuticals. FDA intends this guidance to assist developers of
medical imaging devices and imaging drug/biological products that
provide image contrast enhancement. The final guidance announced in
this document fulfills FDA's commitment to issue guidance called for by
the commitment letter. The guidance supercedes the draft guidance of
the same title dated September 30, 2008.
DATES: Submit written or electronic comments on agency guidances at
any time.
ADDRESSES: Submit written requests for single copies of this guidance
to the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed
adhesive label to assist that office in processing your requests.
Submit written comments on the guidance to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852. Submit electronic comments to https://www.regulations.gov. See the SUPPLEMENTARY INFORMATION section for
electronic access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Patricia Y. Love, Office of
Combination Products (HFG-3), Office of the Commissioner, Food and Drug
Administration, 15800 Crabbs Branch Way, Rockville, MD 20855, 301-427-
1934.
SUPPLEMENTARY INFORMATION:
I. Background
As part of the Medical Device User Fee Amendments of 2007 (MDUFA)
Commitment for the Performance Goals and Procedures, Item I.N of the
September 27, 2007, commitment letter, FDA agreed to publish draft
guidance by September 30, 2008, for medical imaging devices for use
with imaging contrast agents or radiopharmaceuticals. Further, the
agreement stated that the ``draft guidance will be published by the end
of FY 2008, and will be subject to a 90-day comment period. FDA will
issue a final guidance within one year of the close of the public
comment period.'' The draft guidance was dated September 30, 2008 (73
FR 58604, October 7, 2008); the comment period closed on January 5,
2009. FDA held meetings with imaging industry stakeholders in July 2008
and August 2009. The final guidance announced in this document fulfills
FDA's commitment to issue final guidance called for by the commitment
letter. The guidance supercedes the draft guidance of the same title
dated September 30, 2008.
FDA is announcing the availability of guidance for industry
entitled ``New Contrast Imaging Indication Considerations for Devices
and Approved Drug and Biological Products.'' FDA intends this guidance
to assist developers of medical imaging devices and imaging drug/
biological products that provide image contrast enhancement.
Particularly, this guidance focuses on the following topics: (1) When
the imaging device developers may add certain new imaging contrast
indications to their device for use with already approved imaging drugs
without a need for a modification of the drug labeling, (2) when the
imaging drug developers may add certain new imaging contrast
indications to their drug for use with already approved imaging devices
without a need for a modification of the device labeling, and (3) what
type of marketing submission(s) imaging drug or imaging device
developers should submit to FDA to request approval/clearance to add a
new imaging contrast indication. FDA intends for the recommendations in
this guidance to promote timely and effective review of, and consistent
and appropriate regulation and labeling for imaging drugs and devices.
FDA notes that during the comment period, certain topics identified
in the docket were beyond the scope of the guidance document. These
comments included requests for guidance on developing specific medical
imaging indications (e.g., myocardial perfusion or breast cancer
imaging) and offered suggestions for the type of acceptable data. FDA
will consider whether separate guidance would be appropriate.
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
agency's current thinking on ``New Contrast Imaging Indication
Considerations for Devices and Approved Drug and Biological Products''.
It does not create or confer any rights for or on any person and does
not operate to bind FDA or the public. An alternative approach may be
used if such approach satisfies the requirements of the applicable
statutes and regulations.
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR 807 have been approved under
[[Page 876]]
OMB control number 0910-0120. The collections of information in 21 CFR
814 have been approved under OMB control number 0910-0231. The
collections of information in 21 CFR 314 have been approved under OMB
control number 0910-0001.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either https://www.fda.gov/RegulatoryInformation/Guidances/ucm122047.htm
or https://www.regulations.gov.
Dated: December 30, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-31307 Filed 1-5-10; 8:45 am]
BILLING CODE 4160-01-S